1
|
Rafi H, Rafiq H, Farhan M. Pharmacological profile of agmatine: An in-depth overview. Neuropeptides 2024; 105:102429. [PMID: 38608401 DOI: 10.1016/j.npep.2024.102429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 03/14/2024] [Accepted: 04/01/2024] [Indexed: 04/14/2024]
Abstract
Agmatine, a naturally occurring polyamine derived from arginine via arginine decarboxylase, has been shown to play multifaceted roles in the mammalian body, impacting a wide range of physiological and pathological processes. This comprehensive review delineates the significant insights into agmatine's pharmacological profile, emphasizing its structure and metabolism, neurotransmission and regulation, and pharmacokinetics and function. Agmatine's biosynthesis is highly conserved across species, highlighting its fundamental role in cellular functions. In the brain, comparable to established neurotransmitters, agmatine acts as a neuromodulator, influencing the regulation, metabolism, and reabsorption of neurotransmitters that are key to mood disorders, learning, cognition, and the management of anxiety and depression. Beyond its neuromodulatory functions, agmatine exhibits protective effects across various cellular and systemic contexts, including neuroprotection, nephroprotection, cardioprotection, and cytoprotection, suggesting a broad therapeutic potential. The review explores agmatine's interaction with multiple receptor systems, including NMDA, α2-adrenoceptors, and imidazoline receptors, elucidating its role in enhancing cell viability, neuronal protection, and synaptic plasticity. Such interactions underpin agmatine's potential in treating neurological diseases and mood disorders, among other conditions. Furthermore, agmatine's pharmacokinetics, including its absorption, distribution, metabolism, and excretion, are discussed, underlining the complexity of its action and the potential for therapeutic application. The safety and efficacy of agmatine supplementation, demonstrated through various animal and human studies, affirm its potential as a beneficial therapeutic agent. Conclusively, the diverse physiological and therapeutic effects of agmatine, spanning neurotransmission, protection against cellular damage, and modulation of various receptor pathways, position it as a promising candidate for further research and clinical application. This review underscores the imperative for continued exploration into agmatine's mechanisms of action and its potential in pharmacology and medicine, promising advances in the treatment of numerous conditions.
Collapse
Affiliation(s)
- Hira Rafi
- Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Biochemistry, University of Karachi, Pakistan.
| | - Hamna Rafiq
- Department of Biochemistry, University of Karachi, Pakistan
| | | |
Collapse
|
2
|
Szabo B. Presynaptic Adrenoceptors. Handb Exp Pharmacol 2024. [PMID: 38755350 DOI: 10.1007/164_2024_714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/18/2024]
Abstract
Presynaptic α2-adrenoceptors are localized on axon terminals of many noradrenergic and non-noradrenergic neurons in the peripheral and central nervous systems. Their activation by exogenous agonists leads to inhibition of the exocytotic release of noradrenaline and other transmitters from the neurons. Most often, the α2A-receptor subtype is involved in this inhibition. The chain of molecular events between receptor occupation and inhibition of the exocytotic release of transmitters has been determined. Physiologically released endogenous noradrenaline elicits retrograde autoinhibition of its own release. Some clonidine-like α2-receptor agonists have been used to treat hypertension. Dexmedetomidine is used for prolonged sedation in the intensive care; It also has a strong analgesic effect. The α2-receptor antagonist mirtazapine increases the noradrenaline concentration in the synaptic cleft by interrupting physiological autoinhibion of release. It belongs to the most effective antidepressive drugs. β2-Adrenoceptors are also localized on axon terminals in the peripheral and central nervous systems. Their activation leads to enhanced transmitter release, however, they are not activated by endogenous adrenaline.
Collapse
Affiliation(s)
- Bela Szabo
- Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
| |
Collapse
|
3
|
Bagán A, Rodriguez-Arévalo S, Taboada-Jara T, Griñán-Ferré C, Pallàs M, Brocos-Mosquera I, Callado LF, Morales-García JA, Pérez B, Diaz C, Fernández-Godino R, Genilloud O, Beljkas M, Oljacic S, Nikolic K, Escolano C. Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease. Pharmaceutics 2023; 15:2381. [PMID: 37896141 PMCID: PMC10610545 DOI: 10.3390/pharmaceutics15102381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 09/14/2023] [Accepted: 09/16/2023] [Indexed: 10/29/2023] Open
Abstract
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer's disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson's disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.
Collapse
Affiliation(s)
- Andrea Bagán
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (A.B.); (S.R.-A.)
| | - Sergio Rodriguez-Arévalo
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (A.B.); (S.R.-A.)
| | - Teresa Taboada-Jara
- Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (T.T.-J.); (C.G.-F.); (M.P.)
| | - Christian Griñán-Ferré
- Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (T.T.-J.); (C.G.-F.); (M.P.)
- Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), National Institute of Health Carlos III, 28029 Madrid, Spain
| | - Mercè Pallàs
- Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (T.T.-J.); (C.G.-F.); (M.P.)
- Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), National Institute of Health Carlos III, 28029 Madrid, Spain
| | - Iria Brocos-Mosquera
- Department of Pharmacology, University of the Basque Country, UPV/EHU, 48940 Leioa, Spain; (I.B.-M.); (L.F.C.)
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, 28029 Madrid, Spain
| | - Luis F. Callado
- Department of Pharmacology, University of the Basque Country, UPV/EHU, 48940 Leioa, Spain; (I.B.-M.); (L.F.C.)
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, 28029 Madrid, Spain
- Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain
| | - José A. Morales-García
- Department of Cell Biology, School of Medicine, Complutense University (UCM), 28040 Madrid, Spain;
| | - Belén Pérez
- Department of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, 08193 Cerdanyola, Spain;
| | - Caridad Diaz
- Fundación MEDINA Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain; (C.D.); (R.F.-G.); (O.G.)
| | - Rosario Fernández-Godino
- Fundación MEDINA Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain; (C.D.); (R.F.-G.); (O.G.)
| | - Olga Genilloud
- Fundación MEDINA Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain; (C.D.); (R.F.-G.); (O.G.)
| | - Milan Beljkas
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia; (M.B.); (S.O.); (K.N.)
| | - Slavica Oljacic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia; (M.B.); (S.O.); (K.N.)
| | - Katarina Nikolic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia; (M.B.); (S.O.); (K.N.)
| | - Carmen Escolano
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (A.B.); (S.R.-A.)
| |
Collapse
|
4
|
Nakamura S, Kibe M, Takehara T, Suzuki T. Direct Catalytic Enantioselective Reaction of α-Isocyanoacetonitriles with Ketimines Using Cinchona Alkaloid Amide-Cu(II) Catalysts. Org Lett 2023; 25:1040-1044. [PMID: 36749377 DOI: 10.1021/acs.orglett.3c00259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The first enantioselective reaction of α-isocyanoacetonitriles was developed. The reaction of various α-isocyanoacetonitriles with ketimines using cinchona alkaloid amide-Cu(II) catalysts afforded imidazolines with consecutive tetrasubstituted stereogenic carbon centers in good yields and high diastereo- and enantioselectivities. The stereoselectivity of the reaction is explained on the basis of the control experiment and density functional theory (DFT) calculations. The products were subsequently converted into chiral compounds. This process highlights the possible use of α-isocyanoacetonitriles for asymmetric and organic syntheses.
Collapse
Affiliation(s)
- Shuichi Nakamura
- Department of Life Science and Applied Chemistry, Graduate School of Engineering, Nagoya Institute of Technology, Gokiso, Showa-ku, Nagoya 466-8555, Japan
| | - Masato Kibe
- Department of Life Science and Applied Chemistry, Graduate School of Engineering, Nagoya Institute of Technology, Gokiso, Showa-ku, Nagoya 466-8555, Japan
| | - Tsunayoshi Takehara
- The Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki-shi, Osaka 567-0047, Japan
| | - Takeyuki Suzuki
- The Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki-shi, Osaka 567-0047, Japan
| |
Collapse
|
5
|
Bennett DF, Goyala A, Statzer C, Beckett CW, Tyshkovskiy A, Gladyshev VN, Ewald CY, de Magalhães JP. Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans via a nischarin I1-imidazoline receptor. Aging Cell 2023; 22:e13774. [PMID: 36670049 PMCID: PMC9924948 DOI: 10.1111/acel.13774] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 12/02/2022] [Accepted: 12/09/2022] [Indexed: 01/22/2023] Open
Abstract
Repurposing drugs capable of extending lifespan and health span has a huge untapped potential in translational geroscience. Here, we searched for known compounds that elicit a similar gene expression signature to caloric restriction and identified rilmenidine, an I1-imidazoline receptor agonist and prescription medication for the treatment of hypertension. We then show that treating Caenorhabditis elegans with rilmenidine at young and older ages increases lifespan. We also demonstrate that the stress-resilience, health span, and lifespan benefits of rilmenidine treatment in C. elegans are mediated by the I1-imidazoline receptor nish-1, implicating this receptor as a potential longevity target. Consistent with the shared caloric-restriction-mimicking gene signature, supplementing rilmenidine to calorically restricted C. elegans, genetic reduction of TORC1 function, or rapamycin treatment did not further increase lifespan. The rilmenidine-induced longevity required the transcription factors FOXO/DAF-16 and NRF1,2,3/SKN-1. Furthermore, we find that autophagy, but not AMPK signaling, was needed for rilmenidine-induced longevity. Moreover, transcriptional changes similar to caloric restriction were observed in liver and kidney tissues in mice treated with rilmenidine. Together, these results reveal a geroprotective and potential caloric restriction mimetic effect by rilmenidine that warrant fresh lines of inquiry into this compound.
Collapse
Affiliation(s)
- Dominic F. Bennett
- Integrative Genomics of Ageing GroupInstitute of Ageing and Chronic Disease, University of LiverpoolLiverpoolUK
| | - Anita Goyala
- Department of Health Sciences and Technology, Laboratory of Extracellular Matrix RegenerationInstitute of Translational Medicine, ETH ZürichSchwerzenbachSwitzerland
| | - Cyril Statzer
- Department of Health Sciences and Technology, Laboratory of Extracellular Matrix RegenerationInstitute of Translational Medicine, ETH ZürichSchwerzenbachSwitzerland
| | - Charles W. Beckett
- Integrative Genomics of Ageing GroupInstitute of Ageing and Chronic Disease, University of LiverpoolLiverpoolUK
| | - Alexander Tyshkovskiy
- Division of Genetics, Department of MedicineBrigham and Women's Hospital, Harvard Medical SchoolBostonMassachusettsUSA,Belozersky Institute of Physico‐Chemical BiologyMoscow State UniversityMoscowRussia
| | - Vadim N. Gladyshev
- Division of Genetics, Department of MedicineBrigham and Women's Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Collin Y. Ewald
- Department of Health Sciences and Technology, Laboratory of Extracellular Matrix RegenerationInstitute of Translational Medicine, ETH ZürichSchwerzenbachSwitzerland
| | - João Pedro de Magalhães
- Integrative Genomics of Ageing GroupInstitute of Ageing and Chronic Disease, University of LiverpoolLiverpoolUK,Present address:
Institute of Inflammation and AgeingUniversity of Birmingham, Queen Elizabeth HospitalBirminghamUK
| |
Collapse
|
6
|
Nadal Rodríguez P, Ghashghaei O, Bagán A, Escolano C, Lavilla R. Heterocycle-Based Multicomponent Reactions in Drug Discovery: From Hit Finding to Rational Design. Biomedicines 2022; 10:biomedicines10071488. [PMID: 35884794 PMCID: PMC9313418 DOI: 10.3390/biomedicines10071488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 06/16/2022] [Accepted: 06/20/2022] [Indexed: 11/16/2022] Open
Abstract
In the context of the structural complexity necessary for a molecule to selectively display a therapeutical action and the requirements for suitable pharmacokinetics, a robust synthetic approach is essential. Typically, thousands of relatively similar compounds should be prepared along the drug discovery process. In this respect, heterocycle-based multicomponent reactions offer advantages over traditional stepwise sequences in terms of synthetic economy, as well as the fast access to chemsets to study the structure activity relationships, the fine tuning of properties, and the preparation of larger amounts for preclinical phases. In this account, we briefly summarize the scientific methodology backing the research line followed by the group. We comment on the main results, clustered according to the targets and, finally, in the conclusion section, we offer a general appraisal of the situation and some perspectives regarding future directions in academic and private research.
Collapse
|
7
|
Bagán A, Morales-García JA, Griñán-Ferré C, Díaz C, Pérez del Palacio J, Ramos MC, Vicente F, Pérez B, Brea J, Loza MI, Pallàs M, Escolano C. Insights into the Pharmacokinetics and In Vitro Cell-Based Studies of the Imidazoline I 2 Receptor Ligand B06. Int J Mol Sci 2022; 23:ijms23105408. [PMID: 35628219 PMCID: PMC9141032 DOI: 10.3390/ijms23105408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Revised: 05/06/2022] [Accepted: 05/06/2022] [Indexed: 02/01/2023] Open
Abstract
The impact of neurodegenerative diseases (ND) is becoming unbearable for humankind due to their vast prevalence and the lack of efficacious treatments. In this scenario, we focused on imidazoline I2 receptors (I2-IR) that are widely distributed in the brain and are altered in patients with brain disorders. We took the challenge of modulating I2-IR by developing structurally new molecules, in particular, a family of bicyclic α-iminophosphonates, endowed with high affinity and selectivity to these receptors. Treatment of two murine models, one for age-related cognitive decline and the other for Alzheimer's disease (AD), with representative compound B06 ameliorated their cognitive impairment and improved their behavioural condition. Furthermore, B06 revealed beneficial in vitro ADME-Tox properties. The pharmacokinetics (PK) and metabolic profile are reported to de-risk B06 for progressing in the preclinical development. To further characterize the pharmacological properties of B06, we assessed its neuroprotective properties and beneficial effect in an in vitro model of Parkinson's disease (PD). B06 rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine (6-OHDA) and showed a crucial anti-inflammatory effect in a cellular model of neuroinflammation. This research reveals B06 as a putative candidate for advancing in the difficult path of drug discovery and supports the modulation of I2-IR as a fresh approach for the therapy of ND.
Collapse
Affiliation(s)
- Andrea Bagán
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain;
| | - José A. Morales-García
- The Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Department of Cell Biology, School of Medicine, Complutense University (UCM), 28040 Madrid, Spain;
| | - Christian Griñán-Ferré
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, 08028 Barcelona, Spain; (C.G.-F.); (M.P.)
| | - Caridad Díaz
- Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain; (C.D.); (J.P.d.P.); (M.C.R.); (F.V.)
| | - José Pérez del Palacio
- Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain; (C.D.); (J.P.d.P.); (M.C.R.); (F.V.)
| | - Maria C. Ramos
- Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain; (C.D.); (J.P.d.P.); (M.C.R.); (F.V.)
| | - Francisca Vicente
- Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain; (C.D.); (J.P.d.P.); (M.C.R.); (F.V.)
| | - Belén Pérez
- Department of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, 08193 Barcelona, Spain;
| | - José Brea
- Innopharma Screening Platform, BioFarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15706 Santiago de Compostela, Spain; (J.B.); (M.I.L.)
| | - María Isabel Loza
- Innopharma Screening Platform, BioFarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15706 Santiago de Compostela, Spain; (J.B.); (M.I.L.)
| | - Mercè Pallàs
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, 08028 Barcelona, Spain; (C.G.-F.); (M.P.)
| | - Carmen Escolano
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain;
- Correspondence:
| |
Collapse
|
8
|
Benzofuranyl-2-imidazoles as imidazoline I 2 receptor ligands for Alzheimer's disease. Eur J Med Chem 2021; 222:113540. [PMID: 34118720 DOI: 10.1016/j.ejmech.2021.113540] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 04/26/2021] [Accepted: 05/10/2021] [Indexed: 12/29/2022]
Abstract
Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable. Acute treatment in mice with 2-(2-benzofuranyl)-2-imidazole, known as LSL60101 (garsevil), showed non-warning properties in the ADMET studies and an optimal pharmacokinetic profile. Moreover, LSL60101 induced hypothermia in mice while decreased pro-apoptotic FADD protein in the hippocampus. In vivo studies in the familial Alzheimer's disease 5xFAD murine model with the representative compound, revealed significant decreases in the protein expression levels of antioxidant enzymes superoxide dismutase and glutathione peroxidase in hippocampus. Overall, LSL60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress.
Collapse
|
9
|
Farooq S, Haq IU, Ullah N. Synthesis, characterization and biological evaluation of N-Mannich base derivatives of 2-phenyl-2-imidazoline as potential antioxidants, enzyme inhibitors, antimicrobials, cytotoxic and anti-inflammatory agents. ARAB J CHEM 2021. [DOI: 10.1016/j.arabjc.2021.103050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
10
|
Malhotra V, Vats M, Nath R, Mehta S, Kumar R, Bhalla M, Sinha JN, Shanker K, Pathak SR. Synthesis and biological evaluation of imidazoline derivatives as potential CNS and CVS agents. Bioorg Med Chem Lett 2020; 30:127595. [PMID: 33031924 DOI: 10.1016/j.bmcl.2020.127595] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 09/24/2020] [Accepted: 09/26/2020] [Indexed: 01/06/2023]
Abstract
A series of substituted imidazoline derivatives were synthesized and characterized. Compounds were tested in-vivo for their antihypertensive, analgesic, antiaggressive, depressant, antidepressant, and ALD50 activities. The compounds 3a, 3c, 4c, 5a, and 6c showed cardiovascular as well as central nervous system activities and are potential candidate as drug among all fifteen compounds tested. All these compounds have shown better activity for antihypertensive, analgesic, antiaggressive, and depressant-antidepressant, properties than reference compounds clonidine, morphine, diazepam, and imipramine respectively. Most of the compounds have shown ALD50 > 500 mg/kg with maximum in 4a and 5a (>1000 mg/kg).
Collapse
Affiliation(s)
- Vineet Malhotra
- Department of Pharmacology & Therapeutics, KGMU, Lucknow, India
| | - Monika Vats
- Department of Chemistry, Biochemistry & Forensic Science, Amity School of Applied Sciences, Amity University Haryana, Gurugram 122413, India
| | - Rajendra Nath
- Department of Pharmacology & Therapeutics, KGMU, Lucknow, India
| | - Simpi Mehta
- Department of Chemistry, Biochemistry & Forensic Science, Amity School of Applied Sciences, Amity University Haryana, Gurugram 122413, India
| | - Rakesh Kumar
- Department of Chemistry, Biochemistry & Forensic Science, Amity School of Applied Sciences, Amity University Haryana, Gurugram 122413, India
| | - Manish Bhalla
- Department of Pharmacology & Therapeutics, KGMU, Lucknow, India
| | - J N Sinha
- Department of Pharmacology & Therapeutics, KGMU, Lucknow, India
| | - K Shanker
- Department of Pharmacology & Therapeutics, KGMU, Lucknow, India
| | - Seeema R Pathak
- Department of Chemistry, Biochemistry & Forensic Science, Amity School of Applied Sciences, Amity University Haryana, Gurugram 122413, India.
| |
Collapse
|
11
|
Bousquet P, Hudson A, García-Sevilla JA, Li JX. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacol Rev 2020; 72:50-79. [PMID: 31819014 DOI: 10.1124/pr.118.016311] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification. For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure. Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades. I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs. Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α 2-adrenoceptor selectivity. Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α 2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome. I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive. I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection. A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor-based first-in-class nonopioid analgesic. The understanding of I3 receptors is relatively limited. Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion. Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.
Collapse
Affiliation(s)
- Pascal Bousquet
- Faculty of Medicine, University of Strasbourg, Strasbourg, France (P.B.); Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada (A.H.); Laboratory of Neuropharmacology, University Research Institute on Health Sciences, University of the Balearic Islands, Palma de Malllorca, Spain (J.A.G.-S.); and Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, New York (J.-X.L.)
| | - Alan Hudson
- Faculty of Medicine, University of Strasbourg, Strasbourg, France (P.B.); Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada (A.H.); Laboratory of Neuropharmacology, University Research Institute on Health Sciences, University of the Balearic Islands, Palma de Malllorca, Spain (J.A.G.-S.); and Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, New York (J.-X.L.)
| | - Jesús A García-Sevilla
- Faculty of Medicine, University of Strasbourg, Strasbourg, France (P.B.); Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada (A.H.); Laboratory of Neuropharmacology, University Research Institute on Health Sciences, University of the Balearic Islands, Palma de Malllorca, Spain (J.A.G.-S.); and Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, New York (J.-X.L.)
| | - Jun-Xu Li
- Faculty of Medicine, University of Strasbourg, Strasbourg, France (P.B.); Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada (A.H.); Laboratory of Neuropharmacology, University Research Institute on Health Sciences, University of the Balearic Islands, Palma de Malllorca, Spain (J.A.G.-S.); and Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, New York (J.-X.L.)
| |
Collapse
|
12
|
Abás S, Rodríguez-Arévalo S, Bagán A, Griñán-Ferré C, Vasilopoulou F, Brocos-Mosquera I, Muguruza C, Pérez B, Molins E, Luque FJ, Pérez-Lozano P, de Jonghe S, Daelemans D, Naesens L, Brea J, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Radan M, Djikic T, Nikolic K, Pallàs M, Callado LF, Escolano C. Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease. J Med Chem 2020; 63:3610-3633. [DOI: 10.1021/acs.jmedchem.9b02080] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Sònia Abás
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| | - Sergio Rodríguez-Arévalo
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| | - Andrea Bagán
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| | - Christian Griñán-Ferré
- Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| | - Foteini Vasilopoulou
- Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| | - Iria Brocos-Mosquera
- Department of Pharmacology, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain
| | - Carolina Muguruza
- Department of Pharmacology, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain
| | - Belén Pérez
- Department of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, E-08193 Barcelona, Spain
| | - Elies Molins
- Institut de Ciència de Materials de Barcelona (CSIC), Campus UAB, E-08193 Cerdanyola, Spain
| | - F. Javier Luque
- Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), and Institute of Theoretical and Computational Chemistry (IQTCUB), University of Barcelona, E-08921 Santa Coloma de Gramanet, Spain
| | - Pilar Pérez-Lozano
- Unit of Pharmaceutical Technology, Pharmacy and Pharmaceutical Technology, and Physical Chemistry Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| | - Steven de Jonghe
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Dirk Daelemans
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Lieve Naesens
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - José Brea
- Innopharma screening platform, BioFarma research group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - M. Isabel Loza
- Innopharma screening platform, BioFarma research group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Elena Hernández-Hernández
- IUNICS University of the Balearic Islands (UIB), and Health Research Institute of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain
| | - Jesús A. García-Sevilla
- IUNICS University of the Balearic Islands (UIB), and Health Research Institute of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain
| | - M. Julia García-Fuster
- IUNICS University of the Balearic Islands (UIB), and Health Research Institute of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain
| | - Milica Radan
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Teodora Djikic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Katarina Nikolic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Mercè Pallàs
- Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| | - Luis F. Callado
- Department of Pharmacology, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain
| | - Carmen Escolano
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
| |
Collapse
|
13
|
Solomon MM, Umoren SA, Quraishi MA, Salman M. Myristic acid based imidazoline derivative as effective corrosion inhibitor for steel in 15% HCl medium. J Colloid Interface Sci 2019; 551:47-60. [DOI: 10.1016/j.jcis.2019.05.004] [Citation(s) in RCA: 92] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2018] [Revised: 04/14/2019] [Accepted: 05/01/2019] [Indexed: 10/26/2022]
|
14
|
Griñán-Ferré C, Vasilopoulou F, Abás S, Rodríguez-Arévalo S, Bagán A, Sureda FX, Pérez B, Callado LF, García-Sevilla JA, García-Fuster MJ, Escolano C, Pallàs M. Behavioral and Cognitive Improvement Induced by Novel Imidazoline I 2 Receptor Ligands in Female SAMP8 Mice. Neurotherapeutics 2019; 16:416-431. [PMID: 30460457 PMCID: PMC6554384 DOI: 10.1007/s13311-018-00681-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
As populations increase their life expectancy, age-related neurodegenerative disorders such as Alzheimer's disease have become more common. I2-Imidazoline receptors (I2-IR) are widely distributed in the central nervous system, and dysregulation of I2-IR in patients with neurodegenerative diseases has been reported, suggesting their implication in cognitive impairment. This evidence indicates that high-affinity selective I2-IR ligands potentially contribute to the delay of neurodegeneration. In vivo studies in the female senescence accelerated mouse-prone 8 mice have shown that treatment with I2-IR ligands, MCR5 and MCR9, produce beneficial effects in behavior and cognition. Changes in molecular pathways implicated in oxidative stress, inflammation, synaptic plasticity, and apoptotic cell death were also studied. Furthermore, treatments with these I2-IR ligands diminished the amyloid precursor protein processing pathway and increased Aβ degrading enzymes in the hippocampus of SAMP8 mice. These results collectively demonstrate the neuroprotective role of these new I2-IR ligands in a mouse model of brain aging through specific pathways and suggest their potential as therapeutic agents in brain disorders and age-related neurodegenerative diseases.
Collapse
Affiliation(s)
- Christian Griñán-Ferré
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain
| | - Foteini Vasilopoulou
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain
| | - Sònia Abás
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain
| | - Sergio Rodríguez-Arévalo
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain
| | - Andrea Bagán
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain
| | - Francesc X Sureda
- Pharmacology Unit, Faculty of Medicine and Health Sciences, University of Rovira and Virgili, C./St. Llorenç 21, 43201, Reus, Tarragona, Spain
| | - Belén Pérez
- Departament of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, 08193, Barcelona, Spain
| | - Luis F Callado
- Department of Pharmacology, University of the Basque Country, UPV/EHU, 48940, Leioa, Bizkaia, Spain
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Leioa, Spain
| | - Jesús A García-Sevilla
- Laboratory of Neuropharmacology, IUNICS and IdISBa, University of the Balearic Islands (UIB), Cra. Valldemossa km 7.5, 07122, Palma de Mallorca, Spain
| | - M Julia García-Fuster
- Laboratory of Neuropharmacology, IUNICS and IdISBa, University of the Balearic Islands (UIB), Cra. Valldemossa km 7.5, 07122, Palma de Mallorca, Spain
| | - Carmen Escolano
- Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain
| | - Mercè Pallàs
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.
| |
Collapse
|
15
|
Cobos-Puc L, Aguayo-Morales H. Cardiovascular Effects Mediated by Imidazoline Drugs: An Update. Cardiovasc Hematol Disord Drug Targets 2019; 19:95-108. [PMID: 29962350 DOI: 10.2174/1871529x18666180629170336] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 05/05/2017] [Accepted: 04/18/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVE Clonidine is a centrally acting antihypertensive drug. Hypotensive effect of clonidine is mediated mainly by central α2-adrenoceptors and/or imidazoline receptors located in a complex network of the brainstem. Unfortunately, clonidine produces side effects such as sedation, mouth dry, and depression. Moxonidine and rilmenidine, compounds of the second generation of imidazoline drugs, with fewer side effects, display a higher affinity for the imidazoline receptors compared with α2-adrenoceptors. The antihypertensive action of these drugs is due to inhibition of the sympathetic outflow primarily through central I1-imidazoline receptors in the RVLM, although others anatomical sites and mechanisms/receptors are involved. Agmatine is regarded as the endogenous ligand for imidazoline receptors. This amine modulates the cardiovascular function. Indeed, when administered in the RVLM mimics the hypotension of clonidine. RESULTS Recent findings have shown that imidazoline drugs also exert biological response directly on the cardiovascular tissues, which can contribute to their antihypertensive response. Currently, new imidazoline receptors ligands are in development. CONCLUSION In the present review, we provide a brief update on the cardiovascular effects of clonidine, moxonidine, rilmenidine, and the novel imidazoline agents since representing an important therapeutic target for some cardiovascular diseases.
Collapse
Affiliation(s)
- Luis Cobos-Puc
- Department of Pharmacology, Faculty of Chemistry, Autonomous University of Coahuila, Saltillo, Mexico
| | - Hilda Aguayo-Morales
- Department of Pharmacology, Faculty of Chemistry, Autonomous University of Coahuila, Saltillo, Mexico
| |
Collapse
|
16
|
Nascimento AR, Gomes F, Machado MV, Gonçalves-de-Albuquerque C, Bousquet P, Tibiriçá E. I 1-imidazoline receptor-mediated cardiovascular and metabolic effects in high-fat diet-induced metabolic syndrome in rats. Auton Neurosci 2018; 217:18-25. [PMID: 30704971 DOI: 10.1016/j.autneu.2018.12.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 11/09/2018] [Accepted: 12/21/2018] [Indexed: 02/06/2023]
Abstract
OBJECTIVES The objective of this study was to investigate the effects of a new I1-imidazoline receptor-selective pyrroline compound on the hemodynamic, metabolic and microvascular alterations in a high-fat diet (HFD)-induced model of metabolic syndrome in rats. METHODS In total, twenty adult male Wistar rats were fed a high-fat diet (HFD, n = 20) for 20 weeks. Thereafter, the rats received a new pyrroline compound selective for I1-imidazoline receptors (LNP599; 10 mg/kg/day) or vehicle (n = 10/group) orally by gavage for 4 weeks. Functional microcirculation was assessed using intravital video microscopy, and structural microcirculation was evaluated using histochemical analysis. RESULTS LNP599 induced concomitant reductions in the SBP, HR and plasma catecholamine levels. The animals treated with this new antihypertensive compound also presented an improvement in body weight and the metabolic parameters related to metabolic syndrome, such as the glucose and lipid profiles. These effects were accompanied by a reversal of the functional and structural capillary rarefaction in the skeletal muscle. CONCLUSIONS The modulation of the sympathetic nervous system by a selective agonist for I1-imidazoline receptors improves the hemodynamic and metabolic parameters in an experimental model of metabolic syndrome. LNP599 can also contribute to the restoration of microcirculatory parameters.
Collapse
Affiliation(s)
- Alessandro R Nascimento
- Laboratory of Cardiovascular Investigation, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil; Faculty of Medicine of the University of Strasbourg, Strasbourg, France.
| | - Fabiana Gomes
- Laboratory of Cardiovascular Investigation, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
| | - Marcus V Machado
- Laboratory of Cardiovascular Investigation, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
| | | | - Pascal Bousquet
- Faculty of Medicine of the University of Strasbourg, Strasbourg, France
| | - Eduardo Tibiriçá
- Laboratory of Cardiovascular Investigation, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
| |
Collapse
|
17
|
Üstün E, Düşünceli SD, Özdemir I. Theoretical analysis of frontier orbitals, electronic transitions, and global reactivity descriptors of M(CO)4L2 type metal carbonyl complexes: a DFT/TDDFT study. Struct Chem 2018. [DOI: 10.1007/s11224-018-1231-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, Husbands SM, Rabiner EA, Gunn RN, Murphy PS, Parker CA, Nutt DJ. Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline 2 Binding Site in Human Brain. J Nucl Med 2018; 59:1597-1602. [PMID: 29523627 DOI: 10.2967/jnumed.118.208009] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 02/21/2018] [Indexed: 11/16/2022] Open
Abstract
The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand. Here, we present the first in vivo characterization of this PET radioligand in humans and assess its test-retest reproducibility. Methods: Fourteen healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling. Six subjects were used in a test-retest assessment, and 8 were used in a pharmacologic evaluation, undergoing a second or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug idazoxan (n = 8; 20, 40, 60, and 80 mg) and the mixed irreversible monoamine oxidase type A/B inhibitor isocarboxazid (n = 4; 50 mg). Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. Results: Brain uptake of 11C-BU99008 was good, with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression. Model selection criteria indicated that the 2-tissue-compartment model was preferred. VT estimates were high in the striatum (105 ± 21 mL⋅cm-3), medium in the cingulate cortex (62 ± 10 mL⋅cm-3), and low in the cerebellum (41 ± 7 mL⋅cm-3). Test-retest reliability was reasonable. The uptake was dose-dependently reduced throughout the brain by pretreatment with idazoxan, with an average block across all regions of about 60% (VT, ∼30 mL⋅cm-3) at the highest dose (80 mg). The median effective dose for idazoxan was 28 mg. Uptake was not blocked by pretreatment with the monoamine oxidase inhibitor isocarboxazid. Conclusion:11C-BU99008 in human PET studies demonstrates good brain delivery, reversible kinetics, heterogeneous distribution, specific binding signal consistent with I2BS distribution, and good test-retest reliability.
Collapse
Affiliation(s)
- Robin J Tyacke
- Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Division of Brain Sciences, Imperial College London, London, United Kingdom
| | - Jim F M Myers
- Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Division of Brain Sciences, Imperial College London, London, United Kingdom
| | - Ashwin Venkataraman
- Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Division of Brain Sciences, Imperial College London, London, United Kingdom
| | - Inge Mick
- Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Division of Brain Sciences, Imperial College London, London, United Kingdom
| | - Samuel Turton
- Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Division of Brain Sciences, Imperial College London, London, United Kingdom
| | - Jan Passchier
- Imanova Limited, Imperial College London, London, United Kingdom
| | - Stephen M Husbands
- Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| | | | - Roger N Gunn
- Imanova Limited, Imperial College London, London, United Kingdom
- Restorative Neurosciences, Imperial College London, London, United Kingdom; and
| | - Philip S Murphy
- Experimental Medicine Imaging, GlaxoSmithKline Research and Development Limited, Stevenage, United Kingdom
| | - Christine A Parker
- Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Division of Brain Sciences, Imperial College London, London, United Kingdom
- Experimental Medicine Imaging, GlaxoSmithKline Research and Development Limited, Stevenage, United Kingdom
| | - David J Nutt
- Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Division of Brain Sciences, Imperial College London, London, United Kingdom
| |
Collapse
|
19
|
Amisten S, Duner P, Asplund O, Mohammed Al-Amily I, Groop L, Salehi A. Activation of imidazoline receptor I 2, and improved pancreatic β-cell function in human islets. J Diabetes Complications 2018; 32:813-818. [PMID: 29996974 DOI: 10.1016/j.jdiacomp.2018.06.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 05/28/2018] [Accepted: 06/19/2018] [Indexed: 12/22/2022]
Abstract
AIM The impact of BL11282, an imidazoline receptor (NISCH) agonist, on potentiation of glucose-stimulated insulin secretion (GSIS) from isolated human non-diabetic (ND) and type 2 diabetic (T2D) islets was investigated. METHODS Analysis of mRNA was performed by RNA-sequencing and qPCR. Insulin and cAMP by RIA and ELISA respectively. RESULTS RNA-sequencing data revealed that NISCH is highly expressed in fat tissues, islets, liver and muscles, with eight detectable splice variants of transcripts in islets. NISCH had a positive correlation with GLP-1 (GLP1R) and GIP (GIPR) receptor transcripts. The expression of NISCH was confirmed by qPCR in human islets. NISCH and GLP1R were comparably higher expressed in mouse islets compared to human islets. GSIS was dose-dependently potentiated by BL11282 from incubated islets of ND and T2D human islet donors. The insulinotropic action of BL11282 was associated with increased cAMP. While the harmful effect of high glucose on reductive capacity of islet cells was enhanced by glibenclamide during long-term culture, it was counteracted by BL11282 or Bt2-cAMP. BL11282 also increased proliferation of INS-1 cells during long-time culture. CONCLUSION Our data suggest that BL11282 potentiates GSIS by an action involving cAMP/PKA system and BL11282 could be an attractive insulinotropic and β-cell protective agent.
Collapse
Affiliation(s)
- Stefan Amisten
- Department of Clinical Science, SUS, Division of Islet Cell Physiology, University of Lund, Sweden
| | - Pontus Duner
- Experimental Cardiovascular Research, University of Lund, Sweden
| | - Olof Asplund
- Diabetes and Endocrinology, University of Lund, Sweden
| | - Israa Mohammed Al-Amily
- Department of Clinical Science, SUS, Division of Islet Cell Physiology, University of Lund, Sweden
| | - Leif Groop
- Diabetes and Endocrinology, University of Lund, Sweden
| | - Albert Salehi
- Department of Clinical Science, SUS, Division of Islet Cell Physiology, University of Lund, Sweden; Department of Neuroscience and Physiology, Metabolic Research Unit, University of Goteborg, Goteborg, Sweden.
| |
Collapse
|
20
|
Zhang D, Liu R, Zhou X. Intramolecular alkene hydroamination and degradation of amidines: divergent behavior of rare earth metal amidinate intermediates. Catal Sci Technol 2018. [DOI: 10.1039/c8cy01481g] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The methods for catalytic intramolecular alkene hydroamination and degradation of amidines have been established. Furthermore, a tandem reconstruction/cyclization of amidines has also been developed.
Collapse
Affiliation(s)
- Dexing Zhang
- Department of Chemistry
- Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials
- Fudan University
- Shanghai 200433
- China
| | - Ruiting Liu
- Department of Chemistry
- Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials
- Fudan University
- Shanghai 200433
- China
| | - Xigeng Zhou
- Department of Chemistry
- Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials
- Fudan University
- Shanghai 200433
- China
| |
Collapse
|
21
|
Lin MH, Hsu CC, Lin J, Cheng JT, Wu MC. Investigation of morin-induced insulin secretion in cultured pancreatic cells. Clin Exp Pharmacol Physiol 2017; 44:1254-1262. [PMID: 28699234 DOI: 10.1111/1440-1681.12815] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Revised: 06/26/2017] [Accepted: 07/06/2017] [Indexed: 12/25/2022]
Abstract
Morin is a flavonoid contained in guava that is known to reduce hyperglycemia in diabetes. Insulin secretion has been demonstrated to increase following the administration of morin. The present study is designed to investigate the potential mechanism(s) of morin-induced insulin secretion in the MIN6 cell line. First, we identified that morin induced a dose-dependent increase in insulin secretion and intracellular calcium content in MIN6 cells. Morin potentiated glucose-stimulated insulin secretion (GSIS). Additionally, we used siRNA for the ablation of imidazoline receptor protein (NISCH) expression in MIN6 cells. Interestingly, the effects of increased insulin secretion by morin and canavanine were markedly reduced in Si-NISCH cells. Moreover, we used KU14R to block imidazoline I3 receptor (I-3R) that is known to enhance insulin release from the pancreatic β-cells. Without influence on the basal insulin secretion, KU14R dose-dependently inhibited the increased insulin secretion induced by morin or efaroxan in MIN6 cells. Additionally, effects of increased insulin secretion by morin or efaroxan were reduced by diazoxide at the dose sufficient to open KATP channels and attenuated by nifedipine at the dose used to inhibit L-type calcium channels. Otherwise, phospholipase C (PLC) is introduced to couple with imidazoline receptor (I-R). The PLC inhibitor dose-dependently inhibited the effects of morin in MIN6 cells. Similar blockade was also observed in protein kinase C (PKC) inhibitor-treated cells. Taken together, we found that morin increases insulin secretion via the activation of I-R in pancreatic cells. Therefore, morin would be useful to develop in the research and treatment of diabetic disorders.
Collapse
Affiliation(s)
- Mang Hung Lin
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung, Taiwan.,Chief Secretary's Office, Chiayi Hospital, Ministry of Health and Welfare, Chiayi, Taiwan
| | - Chia-Chen Hsu
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung, Taiwan
| | - Jenshinn Lin
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung, Taiwan
| | - Juei Tang Cheng
- Department of Medical Research, Chi-Mei Medical Center, Tainan, Taiwan.,Institute of Medical Science, College of Health Science, Chang Jung Christian University, Tainan, Taiwan
| | - Ming Chang Wu
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung, Taiwan
| |
Collapse
|
22
|
Zheng JF, Hu XN, Xu Z, Cai DC, Shen TL, Huang PQ. Substrate-Controlled Chemoselective Reactions of Isocyanoacetates with Amides and Lactams. J Org Chem 2017; 82:9693-9703. [DOI: 10.1021/acs.joc.7b01768] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jian-Feng Zheng
- Department of Chemistry,
Fujian Provincial Key Laboratory of Chemical Biology, iChEM (Collaborative
Innovation Center of Chemistry for Energy Materials), College of Chemistry
and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China
| | - Xiu-Ning Hu
- Department of Chemistry,
Fujian Provincial Key Laboratory of Chemical Biology, iChEM (Collaborative
Innovation Center of Chemistry for Energy Materials), College of Chemistry
and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China
| | - Zhen Xu
- Department of Chemistry,
Fujian Provincial Key Laboratory of Chemical Biology, iChEM (Collaborative
Innovation Center of Chemistry for Energy Materials), College of Chemistry
and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China
| | - Dong-Cheng Cai
- Department of Chemistry,
Fujian Provincial Key Laboratory of Chemical Biology, iChEM (Collaborative
Innovation Center of Chemistry for Energy Materials), College of Chemistry
and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China
| | - Tai-Long Shen
- Department of Chemistry,
Fujian Provincial Key Laboratory of Chemical Biology, iChEM (Collaborative
Innovation Center of Chemistry for Energy Materials), College of Chemistry
and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China
| | - Pei-Qiang Huang
- Department of Chemistry,
Fujian Provincial Key Laboratory of Chemical Biology, iChEM (Collaborative
Innovation Center of Chemistry for Energy Materials), College of Chemistry
and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China
| |
Collapse
|
23
|
Comparative pharmacodynamic analysis of imidazoline compounds using rat model of ocular mydriasis with a test of quantitative structure–activity relationships. J Pharm Biomed Anal 2017; 144:122-128. [DOI: 10.1016/j.jpba.2017.03.053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 03/08/2017] [Accepted: 03/26/2017] [Indexed: 11/23/2022]
|
24
|
Di Cesare Mannelli L, Ghelardini C, Micheli L, Del Bello F, Giannella M, Piergentili A, Pigini M, Quaglia W. Synergic stimulation of serotonin 5-HT1A receptor and α2-adrenoceptors for neuropathic pain relief: Preclinical effects of 2-substituted imidazoline derivatives. Eur J Pharmacol 2017. [DOI: 10.1016/j.ejphar.2017.06.023] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
25
|
Lin MH, Hsu CC, Lin J, Cheng JT, Wu MC. Identification of morin as an agonist of imidazoline I-3 receptor for insulin secretion in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 2017; 390:997-1003. [PMID: 28689255 DOI: 10.1007/s00210-017-1399-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 06/28/2017] [Indexed: 10/19/2022]
Abstract
Morin is a flavonoid contained in guava that is known to reduce hyperglycemia in diabetics. Morin has been demonstrated to increase plasma insulin. However, the mechanism(s) remains unknown. The present study is designed to investigate the effect of morin on the imidazoline receptor (I-R) that regulates insulin secretion. We used Chinese hamster ovary (CHO) cells transfected with an I-R expression construct (NISCH-CHO-K1 cells) to identify the direct effect of morin on the I-R. Moreover, the imidazoline I3 receptor (I-3R) is known to be present in pancreatic β cells and involved in insulin secretion. Therefore, we applied a specific antagonist (KU14R) to block I-3R in diabetic rats. Additionally, the effect of morin on insulin secretion was characterized in isolated pancreatic islets. Morin decreased blood glucose levels by increasing plasma insulin levels in diabetic rats. In CHO cells expressing an I-R, morin increased calcium influx in a dose-dependent manner. Additionally, KU14R dose-dependently inhibited the morin-induced effects, including hypoglycemia and the increase in insulin secretion and plasma C-peptide levels, in diabetic rats. Furthermore, morin enhanced insulin secretion from isolated pancreatic islets, and this effect was also dose-dependently inhibited by KU14R. Phospholipase C (PLC) is known to couple with the I-R, and a PLC inhibitor dose-dependently attenuated the insulin secretion induced by morin in isolated pancreatic islets. Taken together, these data suggest that morin can activate I-3R to enhance insulin secretion. Therefore, it would be useful to develop morin into a treatment for diabetic disorders.
Collapse
Affiliation(s)
- Mang Hung Lin
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung City, Taiwan, 90801.,Chief Secretary's Office, Chiayi Hospital, Ministry of Health and Welfare, Chiayi City, Taiwan, 60001
| | - Chia-Chen Hsu
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung City, Taiwan, 90801
| | - Jenshinn Lin
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung City, Taiwan, 90801
| | - Juei-Tang Cheng
- Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan, 73101. .,Institute of Medical Science, College of Health Science, Chang Jung Christian University, Guei-Ren, Tainan City, Taiwan, 71101.
| | - Ming Chang Wu
- Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung City, Taiwan, 90801.
| |
Collapse
|
26
|
Abás S, Erdozain AM, Keller B, Rodríguez-Arévalo S, Callado LF, García-Sevilla JA, Escolano C. Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline I 2 Receptor Ligands. ACS Chem Neurosci 2017; 8:737-742. [PMID: 28029766 DOI: 10.1021/acschemneuro.6b00426] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The imidazoline I2 receptors (I2-IRs) are widely distributed in the brain, and I2-IR ligands may have therapeutic potential as neuroprotective agents. Since structural data for I2-IR remains unknown, the discovery of selective I2-IR ligands devoid of α2-adrenoceptor (α2-AR) affinity is likely to provide valuable tools in defining the pharmacological characterization of these receptors. We report the pharmacological characterization of a new family of (2-imidazolin-4-yl)phosphonates. Radioligand binding studies showed that they displayed a higher affinity for I2-IRs than idazoxan, and high I2/α2 selectivity. In vivo studies in mice showed that acute treatments with 1b and 2c significantly increased p-FADD/FADD ratio (an index of cell survival) in the hippocampus when compared with vehicle-treated controls. Additionally, acute and repeated treatments with 2c, but not with 1b, markedly reduced hippocampal p35 cleavage into neurotoxic p25. The present results indicate a neuroprotective potential of (2-imidazolin-4-yl)phosphonates acting at I2-IRs.
Collapse
Affiliation(s)
- Sònia Abás
- Laboratory
of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology,
Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences,
and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Amaia M. Erdozain
- Department
of Pharmacology, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain
- Centro
de Investigación Biomédica en Red de Salud Mental, CIBERSAM
| | - Benjamin Keller
- Laboratory
of Neuropharmacology, IUNICS/IdISPa, University of the Balearic Islands (UIB), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain
| | - Sergio Rodríguez-Arévalo
- Laboratory
of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology,
Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences,
and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Luis F. Callado
- Department
of Pharmacology, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain
- Centro
de Investigación Biomédica en Red de Salud Mental, CIBERSAM
| | - Jesús A. García-Sevilla
- Laboratory
of Neuropharmacology, IUNICS/IdISPa, University of the Balearic Islands (UIB), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain
| | - Carmen Escolano
- Laboratory
of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology,
Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences,
and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| |
Collapse
|
27
|
Dardonville C, Caine BA, Navarro de la Fuente M, Martín Herranz G, Corrales Mariblanca B, Popelier PLA. Substituent effects on the basicity (pKa) of aryl guanidines and 2-(arylimino)imidazolidines: correlations of pH-metric and UV-metric values with predictions from gas-phase ab initio bond lengths. NEW J CHEM 2017. [DOI: 10.1039/c7nj02497e] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The AIBLHiCoS method accurately predicts the pKa values of 2-(arylimino)imidazolidines using only a single ab initio bond length.
Collapse
Affiliation(s)
| | - Beth A. Caine
- Manchester Institute of Biotechnology (MIB)
- Manchester
- UK
- School of Chemistry
- Univ. of Manchester
| | | | | | | | - Paul L. A. Popelier
- Manchester Institute of Biotechnology (MIB)
- Manchester
- UK
- School of Chemistry
- Univ. of Manchester
| |
Collapse
|
28
|
Fehér Á, Tóth VE, Al-Khrasani M, Balogh M, Lázár B, Helyes Z, Gyires K, Zádori ZS. Analysing the effect of I 1 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology 2016; 25:107-118. [PMID: 27873165 DOI: 10.1007/s10787-016-0299-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 11/13/2016] [Indexed: 12/28/2022]
Abstract
Imidazoline receptors (IRs) have been recognized as promising targets in the treatment of numerous diseases; and moxonidine and rilmenidine, agonists of I1-IRs, are widely used as antihypertensive agents. Some evidence suggests that IR ligands may induce anti-inflammatory effects acting on I1-IRs or other molecular targets, which could be beneficial in patients with inflammatory bowel disease (IBD). On the other hand, several IR ligands may stimulate also alpha2-adrenoceptors, which were earlier shown to inhibit, but in more recent studies to rather aggravate colitis. Hence, this study aimed to analyse for the first time the effect of various I1-IR ligands on intestinal inflammation. Colitis was induced in C57BL/6 mice by adding dextran sulphate sodium (DSS) to the drinking water for 7 days. Mice were treated daily with different IR ligands: moxonidine and rilmenidine (I1-IR agonists), AGN 192403 (highly selective I1-IR ligand, putative antagonist), efaroxan (I1-IR antagonist), as well as with the endogenous IR agonists agmatine and harmane. It was found that moxonidine and rilmenidine at clinically relevant doses, similarly to the other IR ligands, do not have a significant impact on the macroscopic and histological signs of DSS-evoked inflammation. Likewise, colonic myeloperoxidase and serum interleukin-6 levels remained unchanged in response to these agents. Thus, our study demonstrates that imidazoline ligands do not influence significantly the severity of DSS-colitis in mice and suggest that they probably neither affect the course of IBD in humans. However, the translational value of these findings needs to be verified with other experimental colitis models and human studies.
Collapse
Affiliation(s)
- Ágnes Fehér
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Viktória E Tóth
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Mahmoud Al-Khrasani
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Mihály Balogh
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Bernadette Lázár
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Zsuzsanna Helyes
- Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary
| | - Klára Gyires
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Zoltán S Zádori
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary.
| |
Collapse
|
29
|
Üstün E, Demir S, Coşkun F, Kaloğlu M, Şahin O, Büyükgüngör O, Özdemir İ. A theoretical insight for solvent effect on myoglobin assay of W(CO)4L2 type novel complexes with DFT/TDDFT. J Mol Struct 2016. [DOI: 10.1016/j.molstruc.2016.07.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Giusepponi M, Cifani C, Micioni Di Bonaventura MV, Mattioli L, Hudson A, Diamanti E, Del Bello F, Giannella M, Mammoli V, Paoletti CD, Piergentili A, Pigini M, Quaglia W. Combined Interactions with I 1-, I 2-Imidazoline Binding Sites and α 2-Adrenoceptors To Manage Opioid Addiction. ACS Med Chem Lett 2016; 7:956-961. [PMID: 27774136 PMCID: PMC5066154 DOI: 10.1021/acsmedchemlett.6b00290] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Accepted: 09/08/2016] [Indexed: 11/29/2022] Open
Abstract
Tolerance and dependence associated with chronic opioid exposure result from molecular, cellular, and neural network adaptations. Such adaptations concern opioid and nonopioid systems, including α2-adrenoceptors (α2-ARs) and I1- and I2-imidazoline binding sites (IBS). Agmatine, one of the hypothesized endogenous ligands of IBS, targeting several systems including α2-ARs and IBS, proved to be able to regulate opioid-induced analgesia and to attenuate the development of tolerance and dependence. Interested in the complex pharmacological profile of agmatine and considering the nature of its targets, we evaluated two series of imidazolines, rationally designed to simultaneously interact with I1-/I2-IBS or I1-/I2-IBS/α2-ARs. The compounds showing the highest affinities for I1-/I2-IBS or I1-/I2-IBS/α2-ARs have been selected for their in vivo evaluation on opiate withdrawal syndrome. Interestingly, 9, displaying I1-/I2-IBS/α2-ARs interaction profile, appears more effective in reducing expression and acquisition of morphine dependence and, therefore, might be considered a promising tool in managing opioid addiction.
Collapse
Affiliation(s)
- Maria
Elena Giusepponi
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Carlo Cifani
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | | | - Laura Mattioli
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Alan Hudson
- Department
of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Eleonora Diamanti
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Fabio Del Bello
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Mario Giannella
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Corinne Dalila Paoletti
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Alessandro Piergentili
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Maria Pigini
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Wilma Quaglia
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| |
Collapse
|
31
|
Ellsworth AA, Magyar CL, Hubbell GE, Theisen CC, Holmes D, Mosey RA. One-pot triflic anhydride-mediated synthesis of 1,2-disubstituted 2-imidazolines from N-(2-haloethyl)amides and amines. Tetrahedron 2016. [DOI: 10.1016/j.tet.2016.08.040] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
32
|
Del Bello F, Cilia A, Carrieri A, Fasano DC, Ghelardini C, Di Cesare Mannelli L, Micheli L, Santini C, Diamanti E, Giannella M, Giorgioni G, Mammoli V, Paoletti CD, Petrelli R, Piergentili A, Quaglia W, Pigini M. The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A
Receptor. ChemMedChem 2016; 11:2287-2298. [DOI: 10.1002/cmdc.201600383] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Revised: 08/30/2016] [Indexed: 11/12/2022]
Affiliation(s)
- Fabio Del Bello
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Antonio Cilia
- Recordati S.p.A.; Drug Discovery; via Civitali 1 20148 Milano (Italy)
| | - Antonio Carrieri
- Department of Pharmacy-Drug Science; University of Bari “Aldo Moro”; Via E. Orabona 4 70125 Bari Italy
| | - Domenico Claudio Fasano
- Department of Pharmacy-Drug Science; University of Bari “Aldo Moro”; Via E. Orabona 4 70125 Bari Italy
| | - Carla Ghelardini
- Department of Neuroscience, Psychology, Drug Research and; Child Health - Neurofarba - Pharmacology and Toxicology Section; University of Florence; Viale Pieraccini 6 50039 Firenze Italy
| | - Lorenzo Di Cesare Mannelli
- Department of Neuroscience, Psychology, Drug Research and; Child Health - Neurofarba - Pharmacology and Toxicology Section; University of Florence; Viale Pieraccini 6 50039 Firenze Italy
| | - Laura Micheli
- Department of Neuroscience, Psychology, Drug Research and; Child Health - Neurofarba - Pharmacology and Toxicology Section; University of Florence; Viale Pieraccini 6 50039 Firenze Italy
| | - Carlo Santini
- School of Science and Technology; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Eleonora Diamanti
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Mario Giannella
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Gianfabio Giorgioni
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Valerio Mammoli
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Corinne Dalila Paoletti
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Riccardo Petrelli
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Alessandro Piergentili
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Wilma Quaglia
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Maria Pigini
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| |
Collapse
|
33
|
Carbon monoxide-releasing properties and DFT/TDDFT analysis of [Mn(CO) 3 (bpy)L]PF 6 type novel manganese complexes. J Organomet Chem 2016. [DOI: 10.1016/j.jorganchem.2016.05.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
34
|
Sączewski F, Kornicka A, Balewski Ł. Imidazoline scaffold in medicinal chemistry: a patent review (2012–2015). Expert Opin Ther Pat 2016; 26:1031-48. [DOI: 10.1080/13543776.2016.1210128] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
35
|
Filipic S, Antic A, Vujovic M, Nikolic K, Agbaba D. A Comparative Study of Chromatographic Behavior and Lipophilicity of Selected Imidazoline Derivatives. J Chromatogr Sci 2016; 54:1137-45. [PMID: 27406126 DOI: 10.1093/chromsci/bmw081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Indexed: 11/14/2022]
Abstract
Chromatographic behavior and lipophilicity of 20 selected imidazoline derivatives were examined by thin-layer chromatography using CN, RP-2, RP-8 and RP-18 as the stationary phases and a mixture of methanol, water and ammonia as the mobile phase. In all examined chromatographic systems, linear relationships were established between retention parameters and the volume fraction of methanol in the mobile phase (r > 0.985, 0.978, 0.981, 0.988 for the CN, RP-2, RP-8 and RP-18, respectively). The highest correlation between the obtained [Formula: see text] values was observed for RP-2 and RP-8 stationary phases. The experimental lipophilicity indices ([Formula: see text], m and C0) obtained from the retention data were used in correlation study with the calculated logP values. Experimentally determined [Formula: see text] values for all investigated chromatographic systems exhibited the highest correlation with the calculated ClogP values (r: 0.880, 0.872, 0.897 and 0.889 for the CN, RP-2, RP-8 and RP-18 stationary phases, respectively). In addition, principal component analysis enables new information about similarity and differences between tested compounds as well as experimental lipophilicity indices and calculated logP values. Performed QSRR analysis showed that the frequency of C-C at topological distance 1 and CATS2D Lipophilic-Lipophilic at lag 01 were important descriptors with influence on the [Formula: see text] values in all the examined chromatographic systems, while the differences in the retention behavior of compounds on the examined stationary phases can be distinguished based on their specific geometrical, electronic and constitutional properties.
Collapse
Affiliation(s)
- Slavica Filipic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Aleksandra Antic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Milena Vujovic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Katarina Nikolic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Danica Agbaba
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| |
Collapse
|
36
|
Butini S, Nikolic K, Kassel S, Brückmann H, Filipic S, Agbaba D, Gemma S, Brogi S, Brindisi M, Campiani G, Stark H. Polypharmacology of dopamine receptor ligands. Prog Neurobiol 2016; 142:68-103. [PMID: 27234980 DOI: 10.1016/j.pneurobio.2016.03.011] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 01/26/2016] [Accepted: 03/15/2016] [Indexed: 01/11/2023]
Abstract
Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinsońs disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.
Collapse
Affiliation(s)
- S Butini
- Department of Biotechnology, Chemistry and Pharmacy, European Research Centre for Drug Discovery and Development, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - K Nikolic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - S Kassel
- Heinrich Heine University Duesseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany
| | - H Brückmann
- Heinrich Heine University Duesseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany
| | - S Filipic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - D Agbaba
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - S Gemma
- Department of Biotechnology, Chemistry and Pharmacy, European Research Centre for Drug Discovery and Development, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - S Brogi
- Department of Biotechnology, Chemistry and Pharmacy, European Research Centre for Drug Discovery and Development, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - M Brindisi
- Department of Biotechnology, Chemistry and Pharmacy, European Research Centre for Drug Discovery and Development, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - G Campiani
- Department of Biotechnology, Chemistry and Pharmacy, European Research Centre for Drug Discovery and Development, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - H Stark
- Heinrich Heine University Duesseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
| |
Collapse
|
37
|
Nakamura S, Yamaji R, Iwanaga M. Enantioselective construction of imidazolines having vicinal tetra-substituted stereocenters by direct Mannich reaction of α-substituted α-isocyanoacetates with ketimines. Chem Commun (Camb) 2016; 52:7462-5. [DOI: 10.1039/c6cc02911f] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Enantioselective direct Mannich-type reaction of ketimines with α-substituted α-isocyanoacetates gave imidazolines having vicinal tetra-substituted stereocenters with high stereoselectivity.
Collapse
Affiliation(s)
- Shuichi Nakamura
- Department of Life Science and Applied Chemistry
- Graduate School of Engineering
- Nagoya Institute of Technology
- Nagoya 466-8555
- Japan
| | - Ryota Yamaji
- Department of Life Science and Applied Chemistry
- Graduate School of Engineering
- Nagoya Institute of Technology
- Nagoya 466-8555
- Japan
| | - Masaru Iwanaga
- Department of Life Science and Applied Chemistry
- Graduate School of Engineering
- Nagoya Institute of Technology
- Nagoya 466-8555
- Japan
| |
Collapse
|
38
|
Ray TS. Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method. Med Hypotheses 2015; 87:48-60. [PMID: 26826641 DOI: 10.1016/j.mehy.2015.12.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2015] [Revised: 12/05/2015] [Accepted: 12/17/2015] [Indexed: 10/22/2022]
Abstract
The drug MDMA, commonly known as ecstasy, produces a specific and distinct open hearted mental state, which led to the creation of a new pharmacological class, "entactogens". Extensive literature on its mechanisms of action has come to characterize MDMA as a "messy" drug with multiple mechanisms, but the consensus is that the distinctive entactogenic effects arise from the release of neurotransmitters, primarily serotonin. I propose an alternative hypothesis: The entactogenic mental state is due to the simultaneous direct activation of imidazoline-1 (I1) and serotonin-2 (5-HT2) receptors by MDMA. This hypothesis emerges from "mental organ" theory, which embodies many hypotheses, the most relevant of which are: "Mental organs" are populations of neurons that all express their defining metabotropic receptor, and each mental organ plays a distinct role in the mind, a role shaped by evolution as mental organs evolve by duplication and divergence. Mental organs are the mechanism by which evolution sculpts the mind. Mental organs can be in or out of consciousness. In order for a mental organ to enter consciousness, three things must happen: The mental organ must be activated directly at its defining receptor. 5-HT2 must be simultaneously activated. One of the functions of activated 5-HT2 is to load other simultaneously activated mental organs fully into consciousness. In some cases THC must be introduced to remove long-term blocks mediated by the cannabinoid system. I propose the "primer/probe" method to test these hypotheses. A "primer" is a drug that selectively activates 5-HT2 (e.g. DOB or MEM) or serotonin-1 (5-HT1) and 5-HT2 (e.g. DOET or 2C-B-fly). A "probe" is a drug that activates a receptor whose corresponding mental organ we wish to load into consciousness in order to understand its role in the mind. The mental organ is loaded into consciousness when the primer and probe are taken together, but not when taken separately. For example, the blood pressure medications rilmenidine and moxonidine are selective for imidazoline-1 and can be used to test the hypothesis that the entactogenic mental effects of MDMA are due to loading the imidazoline-1 mental organ into consciousness. The primer/probe method is not limited to testing the specific hypothesis about MDMA and imidazoline, but is a general method for studying the role of mental organs in the mind. For example, the role of dopamine mental organs can be studied by using Parkinson's drugs such as ropinirole or pramipexole as probes.
Collapse
Affiliation(s)
- Thomas S Ray
- Department of Biology, University of Oklahoma, Norman, OK 73069, United States.
| |
Collapse
|
39
|
Caprioli G, Mammoli V, Ricciutelli M, Sagratini G, Ubaldi M, Domi E, Mennuni L, Sabatini C, Galimberti C, Ferrari F, Milia C, Comi E, Lanza M, Giannella M, Pigini M, Del Bello F. Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation. Eur J Pharmacol 2015; 769:219-24. [PMID: 26593429 DOI: 10.1016/j.ejphar.2015.11.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 11/12/2015] [Accepted: 11/13/2015] [Indexed: 11/20/2022]
Abstract
Tolerance to opioid administration represents a serious medical alert in different chronic conditions. This study compares the effects of the imidazoline compounds 1, 2, and 3 on morphine tolerance in an animal model of inflammatory pain in the rat. 1, 2, and 3 have been selected in that, although bearing a common scaffold, preferentially bind to α2-adrenoceptors, imidazoline I2 receptors, or both systems, respectively. Such compounds have been tested in vivo by measuring the paw withdrawal threshold to mechanical pressure after complete Freund's adjuvant injection. To determine the ligand levels in rat plasma, an HPLC-mass spectrometry method has been developed. All the compounds significantly reduced the induction of morphine tolerance, showing different potency and duration of action. Indeed, the selective imidazoline I2 receptor interaction (2) restored the analgesic response by maintaining the same time-dependent profile observed after a single morphine administration. Differently, the selective α2C-adrenoceptor activation (1) or the combination between α2C-adrenoceptor activation and imidazoline I2 receptor engagement (3) promoted a change in the temporal profile of morphine analgesia by maintaining a mild but long lasting analgesic effect. Interestingly, the kinetics of compounds in rat plasma supported the pharmacodynamic data. Therefore, this study highlights that both peculiar biological profile and bioavailability of such ligands complement each other to modulate the reduction of morphine tolerance. Based on these observations, 1-3 can be considered useful leads in the design of new drugs able to turn off the undesired tolerance induced by opioids.
Collapse
Affiliation(s)
- Giovanni Caprioli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Massimo Ricciutelli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Gianni Sagratini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Massimo Ubaldi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| | - Esi Domi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| | - Laura Mennuni
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Sabatini
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Galimberti
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Flora Ferrari
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Milia
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy; PhD program in Neuroscience, University of Milan-Bicocca, Italy
| | - Eleonora Comi
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy; PhD program in Neuroscience, University of Milan-Bicocca, Italy
| | - Marco Lanza
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy.
| |
Collapse
|
40
|
Tydlitát J, Bureš F, Růžičková Z. Phenylalanine-Derived Imidazolines Bearing Heteroaromatic Pendants: Synthesis, Characterization, and Application in the AsymmetricHenryReaction. Helv Chim Acta 2015. [DOI: 10.1002/hlca.201500128] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
41
|
Canavanine activates imidazoline I-2 receptors to reduce hyperglycemia in type 1-like diabetic rats. Chem Biol Interact 2015; 240:304-9. [DOI: 10.1016/j.cbi.2015.08.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2015] [Revised: 08/23/2015] [Accepted: 08/28/2015] [Indexed: 11/21/2022]
|
42
|
Amitani M, Cheng KC, Asakawa A, Amitani H, Kairupan TS, Sameshima N, Shimizu T, Hashiguchi T, Inui A. Allantoin ameliorates chemically-induced pancreatic β-cell damage through activation of the imidazoline I3 receptors. PeerJ 2015; 3:e1105. [PMID: 26290782 PMCID: PMC4540048 DOI: 10.7717/peerj.1105] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 06/25/2015] [Indexed: 01/01/2023] Open
Abstract
Objective. Allantoin is the primary active compound in yams (Dioscorea spp.). Recently, allantoin has been demonstrated to activate imidazoline 3 (I3) receptors located in pancreatic tissues. Thus, the present study aimed to investigate the role of allantoin in the effect to improve damage induced in pancreatic β-cells by streptozotocin (STZ) via the I3 receptors. Research Design and Methods. The effect of allantoin on STZ-induced apoptosis in pancreatic β-cells was examined using the ApoTox-Glo triplex assay, live/dead cell double staining assay, flow cytometric analysis, and Western blottings. The potential mechanism was investigated using KU14R: an I3 receptor antagonist, and U73122: a phospholipase C (PLC) inhibitor. The effects of allantoin on serum glucose and insulin secretion were measured in STZ-treated rats. Results. Allantoin attenuated apoptosis and cytotoxicity and increased the viability of STZ-induced β-cells in a dose-dependent manner; this effect was suppressed by KU14R and U73112. Allantoin decreased the level of caspase-3 and increased the level of phosphorylated B-cell lymphoma 2 (Bcl-2) expression detected by Western blotting. The improvement in β-cells viability was confirmed using flow cytometry analysis. Daily injection of allantoin for 8 days in STZ-treated rats significantly lowered plasma glucose and increased plasma insulin levels. This action was inhibited by treatment with KU14R. Conclusion. Allantoin ameliorates the damage of β-cells induced by STZ. The blockade by pharmacological inhibitors indicated that allantoin can activate the I3 receptors through a PLC-related pathway to decrease this damage. Therefore, allantoin and related analogs may be effective in the therapy for β-cell damage.
Collapse
Affiliation(s)
- Marie Amitani
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Kai-Chun Cheng
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Akihiro Asakawa
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Haruka Amitani
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Timothy Sean Kairupan
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Nanami Sameshima
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Toshiaki Shimizu
- Department of Laboratory and Vascular Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Teruto Hashiguchi
- Department of Laboratory and Vascular Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| | - Akio Inui
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima , Japan
| |
Collapse
|
43
|
Chao PC, Chang CH, Niu HS, Huang GC, Chen LJ, Cheng JT. Canavanine increases glucose uptake in C2 C12 cells through the activation of imidazoline I-2B receptors. Clin Exp Pharmacol Physiol 2015; 42:1045-50. [PMID: 26192192 DOI: 10.1111/1440-1681.12464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Revised: 06/27/2015] [Accepted: 07/10/2015] [Indexed: 11/29/2022]
Abstract
Canavanine is a guanidinium derivative that contains the basic structure of the ligand(s) of imidazoline receptor (I-R). Canavanine has been reported to activate the imidazoline I-3 receptor (I-3R) both in vivo and in vitro. Additionally, the activation of the imidazoline I-2B receptor (I-2BR) by guanidinium derivatives may increase glucose uptake. Therefore, the effect of canavanine on the I-2BR was investigated in the present study. Glucose uptake into cultured C2 C12 cells was determined using the radio-ligated tracer 2-[(14) C]-deoxy-glucose. The changes in 5' AMP-activated protein kinase (AMPK) expression were also identified using Western blotting analysis. The canavanine-induced glucose uptake was inhibited in a dose-dependent manner by BU224 (0.01-1 μmol/L), which is a specific I-2BR antagonist, in the C2 C12 cells. Additionally, the canavanine-stimulated AMPK phosphorylation and glucose transporter (GLUT4) expression were also sensitive to BU224 inhibition in the C2 C12 cells. Moreover, both canavanine-stimulated glucose uptake and AMPK phosphorylation were attenuated by high concentrations of amiloride (1-2 μmol/L), which is another established I-2BR inhibitor, in a dose-dependent manner in C2 C12 cells. Additionally, compound C abolished the canavanine-induced glucose uptake and AMPK phosphorylation at a concentration (0.1 μmol/L) sufficient to inhibit AMPK. In conclusion, these data demonstrated that canavanine has an ability to activate I-2BR through the AMPK pathway to increase glucose uptake, which indicates I-2BR as a new target for diabetic therapy.
Collapse
Affiliation(s)
- Pin-Chun Chao
- Bachelor Program of Senior Services, College of Humanities and Social Sciences, Southern Taiwan University of Science and Technology, Yong Kang, Tainan City, Taiwan
| | - Chin-Hong Chang
- Department of Neurosurgery, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan.,Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan
| | - Ho-Shan Niu
- Department of Nursing, Tzu Chi College of Technology, Hualien City, Taiwan
| | - Gin-Chi Huang
- Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan
| | - Li-Jen Chen
- Department of Nursing, Tzu Chi College of Technology, Hualien City, Taiwan
| | - Juei-Tang Cheng
- Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan.,Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan.,Institute of Medical Sciences, Chang Jung Christian University, Guei-Ren, Tainan City, Taiwan
| |
Collapse
|
44
|
Krasavin M. Biologically active compounds based on the privileged 2-imidazoline scaffold: The world beyond adrenergic/imidazoline receptor modulators. Eur J Med Chem 2015; 97:525-37. [DOI: 10.1016/j.ejmech.2014.11.028] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Revised: 11/12/2014] [Accepted: 11/14/2014] [Indexed: 01/04/2023]
|
45
|
Del Bello F, Bargelli V, Cifani C, Gratteri P, Bazzicalupi C, Diamanti E, Giannella M, Mammoli V, Matucci R, Micioni Di Bonaventura MV, Piergentili A, Quaglia W, Pigini M. Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation. ACS Med Chem Lett 2015; 6:496-501. [PMID: 26005521 DOI: 10.1021/acsmedchemlett.5b00115] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 04/03/2015] [Indexed: 01/25/2023] Open
Abstract
Pharmacological studies have suggested that I1-imidazoline receptors are involved in the regulation of cardiovascular function and that selective I1-agonists, devoid of the side effects associated with the common hypotensive α2-adrenoreceptor agonists, might be considered as a second generation of centrally acting antihypertensives. Therefore, in the present study, inspired by the antihypertensive behavior of our selective I1-agonist 4, we designed, prepared, and studied the novel analogues 5-9. A selective I1-profile, associated with significant hemodinamic effects, was displayed by 5, 8, and 9. Interestingly, the highest potency and longest lasting activity displayed by 8 (carbomethyline) suggested that van der Waals interactions, promoted by the ortho methyl decoration of its aromatic moiety, are particularly advantageous. In addition, in analogy to what was noted for (S)-(+)-4, the observation that only (S)-(+)-8 displayed significant hemodynamic effects unequivocally confirmed the stereospecific nature of the I1 proteins.
Collapse
Affiliation(s)
- Fabio Del Bello
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Valentina Bargelli
- Department
NEUROFARBA, Preclinical and Clinical Pharmacology, University of Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Carlo Cifani
- School
of Pharmacy, Pharmacology Unit, University of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Paola Gratteri
- Department NEUROFARBA, Pharmaceutical and Nutraceutical Section and Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy
| | - Carla Bazzicalupi
- Department
of Chemistry Ugo Schiff, University of Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy
| | - Eleonora Diamanti
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Mario Giannella
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Rosanna Matucci
- Department
NEUROFARBA, Preclinical and Clinical Pharmacology, University of Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | | | - Alessandro Piergentili
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Wilma Quaglia
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Maria Pigini
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| |
Collapse
|
46
|
Abás S, Estarellas C, Javier Luque F, Escolano C. Easy access to (2-imidazolin-4-yl)phosphonates by a microwave assisted multicomponent reaction. Tetrahedron 2015. [DOI: 10.1016/j.tet.2015.03.065] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
In vivo evaluation of a new 18F-labeled PET ligand, [18F]FEBU, for the imaging of I2-imidazoline receptors. Nucl Med Biol 2015; 42:406-12. [DOI: 10.1016/j.nucmedbio.2014.12.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 12/01/2014] [Accepted: 12/19/2014] [Indexed: 11/20/2022]
|
48
|
Filipic S, Elek M, Nikolic K, Agbaba D. Quantitative structure-retention relationship modeling of the retention behavior of guanidine and imidazoline derivatives in reversed-phase thin-layer chromatography. JPC-J PLANAR CHROMAT 2015. [DOI: 10.1556/jpc.28.2015.2.6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
49
|
Gasparik V, Greney H, Schann S, Feldman J, Fellmann L, Ehrhardt JD, Bousquet P. Synthesis and Biological Evaluation of 2-Aryliminopyrrolidines as Selective Ligands for I1 Imidazoline Receptors: Discovery of New Sympatho-Inhibitory Hypotensive Agents with Potential Beneficial Effects in Metabolic Syndrome. J Med Chem 2014; 58:878-87. [DOI: 10.1021/jm501456p] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Vincent Gasparik
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Hugues Greney
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Stephan Schann
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Josiane Feldman
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Lyne Fellmann
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Jean-Daniel Ehrhardt
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Pascal Bousquet
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| |
Collapse
|
50
|
Yang TT, Niu HS, Chen LJ, Ku PM, Lin KC, Cheng JT. Canavanine induces insulin release via activation of imidazoline I3 receptors. Clin Exp Pharmacol Physiol 2014; 42:263-8. [PMID: 25482045 DOI: 10.1111/1440-1681.12348] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Revised: 11/18/2014] [Accepted: 11/26/2014] [Indexed: 12/01/2022]
Abstract
The aim of the present study was to identify the effect of canavanine on the imidazoline receptor because canavanine is a guanidinium derivative that has a similar structure to imidazoline receptor ligands. Transfected Chinese hamster ovary-K1 cells expressing imidazoline receptors (nischarin (NISCH)-CHO-K1 cells) were used to elucidate the direct effects of canavanine on imidazoline receptors. In addition, the imidazoline I3 receptor has been implicated in stimulation of insulin secretion from pancreatic β-cells. Wistar rats were used to investigate the effects of canavanine (0.1, 1 and 2.5 mg/kg, i.v.) on insulin secretion. In addition the a specific I3 receptor antagonist KU14R (4 or 8 mg/kg, i.v.) was used to block I3 receptors. Canavanine decreased blood glucose by increasing plasma insulin in rats. In addition, canavanine increased calcium influx into NISCH-CHO-K1 cells in a manner similar to agmatine, the endogenous ligand of imidazoline receptors. Moreover, KU12R dose-dependently attenuated canavanine-induced insulin secretion in HIT-T15 pancreatic β-cells and in the plasma of rats. The data suggest that canavanine is an agonist of I3 receptors both in vivo and in vitro. Thus, canavanine would be a useful tool in imidazoline receptor research.
Collapse
Affiliation(s)
- Ting-Ting Yang
- The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Yanchao, Kaohsiung City, Taiwan
| | | | | | | | | | | |
Collapse
|